{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"TransCode Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"RNAZ"},"Address":{"label":"Address","value":"6 LIBERTY SQUARE,SUITE 2382, BOSTON, Massachusetts, 02109, United States"},"Phone":{"label":"Phone","value":"+1 857 837-3099"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others."},"CompanyUrl":{"label":"Company Url","value":"https://www.transcodetherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Daniel R. Vlock","title":"Chief Medical Officer"},{"name":"Susan Duggan","title":"Senior Vice President-Operations"},{"name":"Thomas A. Fitzgerald","title":"President, CEO, CFO, Director & VP-Administration"},{"name":"Zdravka Medarova","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}